Skip Navigation


Brain Advance Access originally published online on February 15, 2006
Brain 2006 129(5):1194-1200; doi:10.1093/brain/awl041
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
129/5/1194    most recent
awl041v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tandé, D.
Right arrow Articles by François, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tandé, D.
Right arrow Articles by François, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis

Dominique Tandé1,2,3, Günter Höglinger4, Thomas Debeir1,2,3, Nils Freundlieb4, Etienne C. Hirsch1,2,3 and Chantal François1,2,3

1 INSERM U679, Neurology and Experimental Therapeutics, 2 Salpetriere Hospital, 3 Pierre and Marie Curie University, Faculty of Medicine, Paris, France and 4 Department of Neurology, Experimental Neurology Unit, Philipps University, Marburg, Germany

Correspondence to: Chantal François, INSERM U679, Laboratoire de Neurologie et Thérapeutique Expérimentale, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, 75651, Paris, cedex 13, France E-mail: cfrancoi{at}ccr.jussieu.fr

We investigated whether there is neurogenesis in the striatum of aged monkeys, and whether dopamine (DA) depletion induces the genesis of new DA neurons in this structure. Six aged macaques received repeated intraperitoneal injections of bromodeoxyuridine (BrdU) over a 3 week period to label dividing cells. Three macaques were injected in parallel with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to decrease dopaminergic innervation of the striatum. The brains were analysed 3 weeks after the last BrdU injection. In MPTP-treated aged macaques, the number of tyrosine hydroxylase (TH) immunoreactive (ir) striatal neurons increased 2.3-fold compared with controls. These TH-ir striatal cells did not express dopamine beta hydroxylase (DBH) but the dopamine transporter (DAT), suggesting that they are functional DA neurons. They were also negative for calbindin (CB), neuropeptide Y (NPY) and parvalbumin (PV), and a small proportion expressed calretinin (CR). This suggests that these cells stained for TH are interneurons. All these cells also co-expressed glutamic acid decarboxylase (GAD). They thus resemble the small, aspiny, GABAergic interneurons. None of the BrdU-labelled cells in the striatum expressed the neuronal markers neuronal nuclei (NeuN), or GAD or TH, and none of TH-ir cells incorporated BrdU. These data indicate that neurogenesis did not occur in the striatum of aged macaques. The new striatal TH-ir neurons observed after DA depletion was therefore derived from pre-existing GABAergic interneurons. Understanding of the molecular signals mediating this phenotypic shift might help in developing novel and elegant strategies for a cell-based therapy for Parkinson's disease that would avoid many of the drawbacks of cell transplantation.

Key Words: primates; Parkinson's disease; neurogenesis; advancing age

Abbreviations: BrdU = bromodeoxyuridine; CB = calbindin; DA = dopamine; DAPI = 4',6'-diamidino-2-phenylindole-dihydrochloride; DAT = dopamine transporter; DBH = dopamine beta hydroxylase; GAD = glutamic acid decarboxylase; ir = immunoreactive; MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NeuN = neuronal nuclei; NPY = neuropeptide Y; PBS = phosphate-buffered saline; PV = parvalbumin; TH = tyrosine hydroxylase

Received November 8, 2005. Revised January 13, 2006. Accepted January 24, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Kowsky, C. Poppelmeyer, E. R. Kramer, B. H. Falkenburger, A. Kruse, R. Klein, and J. B. Schulz
RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals
PNAS, December 11, 2007; 104(50): 20049 - 20054.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
W. San Sebastian, J. Guillen, M. Manrique, S. Belzunegui, E. Ciordia, A. Izal-Azcarate, P. Garrido-Gil, M. Vazquez-Claverie, and M. R. Luquin
Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft
Brain, May 1, 2007; 130(5): 1306 - 1316.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
M. Geraerts, O. Krylyshkina, Z. Debyser, and V. Baekelandt
Concise Review: Therapeutic Strategies for Parkinson Disease Based on the Modulation of Adult Neurogenesis
Stem Cells, February 1, 2007; 25(2): 263 - 270.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
P. Huot, M. Levesque, and A. Parent
The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea
Brain, January 1, 2007; 130(1): 222 - 232.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.